Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Article
  • Published:

FOXM1 promotes neurofibromatosis type 1-associated malignant peripheral nerve sheath tumor progression in a NUF2-dependent manner

Cancer Gene Therapy volume 30, pages 1390–1402 (2023)Cite this article

Subjects

Abstract

Malignant peripheral nerve sheath tumors (MPNSTs) are aggressive soft-tissue sarcomas characterized by poor prognosis and low drug response rates. Traditional chemo/radiotherapies show only mild benefits for patients with MPNSTs, and no targeted therapy is available in the clinic. A better understanding of the molecular background of MPNSTs is critical for the development of effective targeted therapies. Forkhead box M1 (FOXM1) has been implicated in the progression of many human malignancies, though its role in MPNSTs is unclear. In this study, using four Gene Expression Omnibus (GEO) datasets and a tissue microarray, we demonstrated that FOXM1 upregulation was associated with poor prognosis in patients with MPNSTs. FOXM1 overexpression and knockdown regulated the proliferation and colony formation of MPNST cells. Using bioinformatics analysis and luciferase reporter assays, we identified NUF2 as a direct downstream target of FOXM1. Both in vitro and in vivo experiments demonstrated that the induction of MPNST cell proliferation by FOXM1 was dependent on elevated NUF2 expression, as NUF2 knockdown abolished the FOXM1-induced proliferation of MPNST cells. Our study showed that the FOXM1–NUF2 axis mediates human MPNST progression and could be a potential therapeutic target.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Upregulation of FOXM1 is correlated with poor prognosis in MPNST patients.
Fig. 2: FOXM1 promotes NF1-associated MPNST cell proliferation in vitro.
Fig. 3: FOXM1 upregulates the expression of NUF2 by binding to its promotor site.
Fig. 4: NUF2 promotes NF1 - associated MPNST cell proliferation in vitro.
Fig. 5: NUF2 is required for FOXM1-induced proliferation of NF1- associated MPNST cells in vitro.
Fig. 6: FOXM1–NUF2 axis promotes NF1-associated MPNST progression in vivo.
Fig. 7: Upregulation of NUF2 is correlated with poor prognosis in MPNST patients.

Data availability

The datasets analyzed during the current study are available from the corresponding author upon reasonable request.

References

  1. Widemann BC, Italiano A. Biology and management of undifferentiated pleomorphic sarcoma, myxofibrosarcoma, and malignant peripheral nerve sheath tumors: state of the art and perspectives. J Clin Oncol. 2018;36:160–7.

    Article  CAS  PubMed  Google Scholar 

  2. Grobmyer SR, Reith JD, Shahlaee A, Bush CH, Hochwald SN. Malignant peripheral nerve sheath tumor: molecular pathogenesis and current management considerations. J Surg Oncol. 2008;97:340–9.

    Article  CAS  PubMed  Google Scholar 

  3. Sun D, Xie XP, Zhang X, Wang Z, Sait SF, Iyer SV, et al. Stem-like cells drive NF1-associated MPNST functional heterogeneity and tumor progression. Cell Stem Cell. 2021;28:1397–410.e4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Evans DG, Baser ME, McGaughran J, Sharif S, Howard E, Moran A. Malignant peripheral nerve sheath tumours in neurofibromatosis 1. J Med Genet. 2002;39:311–4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Kolberg M, Høland M, Agesen TH, Brekke HR, Liestøl K, Hall KS, et al. Survival meta-analyses for >1800 malignant peripheral nerve sheath tumor patients with and without neurofibromatosis type 1. Neuro Oncol. 2013;15:135–47.

    Article  CAS  PubMed  Google Scholar 

  6. Reilly KM, Kim A, Blakely J, Ferner RE, Gutmann DH, Legius E, et al. Neurofibromatosis type 1-associated MPNST state of the science: outlining a research agenda for the future. J Natl Cancer Inst. 2017;109:djx124.

    Article  PubMed  PubMed Central  Google Scholar 

  7. van Noesel MM, Orbach D, Brennan B, Kelsey A, Zanetti I, de Salvo GL, et al. Outcome and prognostic factors in pediatric malignant peripheral nerve sheath tumors: an analysis of the European Pediatric Soft Tissue Sarcoma Group (EpSSG) NRSTS-2005 prospective study. Pediatr Blood Cancer. 2019;66:e27833.

    Article  PubMed  Google Scholar 

  8. Widemann BC. Current status of sporadic and neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors. Curr Oncol Rep. 2009;11:322–8.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Legius E, Marchuk DA, Collins FS, Glover TW. Somatic deletion of the neurofibromatosis type 1 gene in a neurofibrosarcoma supports a tumour suppressor gene hypothesis. Nat Genet. 1993;3:122–6.

    Article  CAS  PubMed  Google Scholar 

  10. Nielsen GP, Stemmer-Rachamimov AO, Ino Y, Moller MB, Rosenberg AE, Louis DN. Malignant transformation of neurofibromas in neurofibromatosis 1 is associated with CDKN2A/p16 inactivation. Am J Pathol. 1999;155:1879–84.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Menon AG, Anderson KM, Riccardi VM, Chung RY, Whaley JM, Yandell DW, et al. Chromosome 17p deletions and p53 gene mutations associated with the formation of malignant neurofibrosarcomas in von Recklinghausen neurofibromatosis. Proc Natl Acad Sci USA. 1990;87:5435–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Kochat V, Raman AT, Landers SM, Tang M, Schulz J, Terranova C, et al. Enhancer reprogramming in PRC2-deficient malignant peripheral nerve sheath tumors induces a targetable de-differentiated state. Acta Neuropathol. 2021;142:565–90.

    Article  CAS  PubMed  Google Scholar 

  13. Liao GB, Li XZ, Zeng S, Liu C, Yang SM, Yang L, et al. Regulation of the master regulator FOXM1 in cancer. Cell Commun Signal. 2018;16:57.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Gartel AL. FOXM1 in cancer: interactions and vulnerabilities. Cancer Res. 2017;77:3135–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Yu L, Liu J, Yan Y, Burwell A, Castro L, Shi M, et al. “Metalloestrogenic” effects of cadmium downstream of G protein-coupled estrogen receptor and mitogen-activated protein kinase pathways in human uterine fibroid cells. Arch Toxicol. 2021;95:1995–2006.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Kruiswijk F, Hasenfuss SC, Sivapatham R, Baar MP, Putavet D, Naipal KA, et al. Targeted inhibition of metastatic melanoma through interference with Pin1-FOXM1 signaling. Oncogene 2016;35:2166–77.

    Article  CAS  PubMed  Google Scholar 

  17. Liu A, Zeng S, Lu X, Xiong Q, Xue Y, Tong L, et al. Overexpression of G2 and S phase-expressed-1 contributes to cell proliferation, migration, and invasion via regulating p53/FoxM1/CCNB1 pathway and predicts poor prognosis in bladder cancer. Int J Biol Macromol. 2019;123:322–34.

    Article  CAS  PubMed  Google Scholar 

  18. Hu G, Yan Z, Zhang C, Cheng M, Yan Y, Wang Y, et al. FOXM1 promotes hepatocellular carcinoma progression by regulating KIF4A expression. J Exp Clin Cancer Res. 2019;38:188.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Yu J, Deshmukh H, Payton JE, Dunham C, Scheithauer BW, Tihan T, et al. Array-based comparative genomic hybridization identifies CDK4 and FOXM1 alterations as independent predictors of survival in malignant peripheral nerve sheath tumor. Clin Cancer Res. 2011;17:1924–34.

    Article  CAS  PubMed  Google Scholar 

  20. Zhang T, Zhou Y, Qi ST, Wang ZB, Qian WP, Ouyang YC, et al. Nuf2 is required for chromosome segregation during mouse oocyte meiotic maturation. Cell Cycle. 2015;14:2701–10.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. DeLuca JG, Howell BJ, Canman JC, Hickey JM, Fang G, Salmon ED. Nuf2 and Hec1 are required for retention of the checkpoint proteins Mad1 and Mad2 to kinetochores. Curr Biol. 2003;13:2103–9.

    Article  CAS  PubMed  Google Scholar 

  22. Ren M, Zhao H, Gao Y, Chen Q, Zhao X, Yue W. NUF2 promotes tumorigenesis by interacting with HNRNPA2B1 via PI3K/AKT/mTOR pathway in ovarian cancer. J Ovarian Res. 2023;16:17.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Jiang X, Jiang Y, Luo S, Sekar K, Koh CKT, Deivasigamani A, et al. Correlation of NUF2 overexpression with poorer patient survival in multiple cancers. Cancer Res Treat. 2021;53:944–61.

    Article  CAS  PubMed  Google Scholar 

  24. Xie X, Jiang S, Li X. Nuf2 is a prognostic-related biomarker and correlated with immune infiltrates in hepatocellular carcinoma. Front Oncol. 2021;11:621373.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Jiang F, Huang X, Yang X, Zhou H, Wang Y. NUF2 expression promotes lung adenocarcinoma progression and is associated with poor prognosis. Front Oncol. 2022;12:795971.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Fu HL, Shao L. Silencing of NUF2 inhibits proliferation of human osteosarcoma Saos-2 cells. Eur Rev Med Pharm Sci. 2016;20:1071–9.

    Google Scholar 

  27. Chen M, Li S, Liang Y, Zhang Y, Luo D, Wang W. Integrative multi-omics analysis of identified NUF2 as a candidate oncogene correlates with poor prognosis and immune infiltration in non-small cell lung cancer. Front Oncol. 2021;11:656509.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Leng R, Meng Y, Sun X, Zhao Y. NUF2 overexpression contributes to epithelial ovarian cancer progression via ERBB3-mediated PI3K-AKT and MAPK signaling axes. Front Oncol. 2022;12:1057198.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Rahrmann EP, Watson AL, Keng VW, Choi K, Moriarity BS, Beckmann DA, et al. Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis. Nat Genet. 2013;45:756–66.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Jessen WJ, Miller SJ, Jousma E, Wu J, Rizvi TA, Brundage ME, et al. MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors. J Clin Invest. 2013;123:340–7.

    Article  CAS  PubMed  Google Scholar 

  31. Kolberg M, Høland M, Lind GE, Ågesen TH, Skotheim RI, Hall KS, et al. Protein expression of BIRC5, TK1, and TOP2A in malignant peripheral nerve sheath tumours—a prognostic test after surgical resection. Mol Oncol. 2015;9:1129–39.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Miller SJ, Jessen WJ, Mehta T, Hardiman A, Sites E, Kaiser S, et al. Integrative genomic analyses of neurofibromatosis tumours identify SOX9 as a biomarker and survival gene. EMBO Mol Med. 2009;1:236–48.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Rahrmann EP, Moriarity BS, Otto GM, Watson AL, Choi K, Collins MH, et al. Trp53 haploinsufficiency modifies EGFR-driven peripheral nerve sheath tumorigenesis. Am J Pathol. 2014;184:2082–98.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Zhang Q, Liu W, Zhang HM, Xie GY, Miao YR, Xia M, et al. hTFtarget: a comprehensive database for regulations of human transcription factors and their targets. Genomics Proteom Bioinforma. 2020;18:120–8.

    Article  Google Scholar 

  35. Zhang X, Lv QL, Huang YT, Zhang LH, Zhou HH. Akt/FoxM1 signaling pathway-mediated upregulation of MYBL2 promotes progression of human glioma. J Exp Clin Cancer Res. 2017;36:105.

    Article  PubMed  PubMed Central  Google Scholar 

  36. Cheng Z, Yu C, Cui S, Wang H, Jin H, Wang C, et al. circTP63 functions as a ceRNA to promote lung squamous cell carcinoma progression by upregulating FOXM1. Nat Commun. 2019;10:3200.

    Article  PubMed  PubMed Central  Google Scholar 

  37. Chand V, Liao X, Guzman G, Benevolenskaya E, Raychaudhuri P. Hepatocellular carcinoma evades RB1-induced senescence by activating the FOXM1-FOXO1 axis. Oncogene 2022;41:3778–90.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Zhou KR, Liu S, Sun WJ, Zheng LL, Zhou H, Yang JH, et al. ChIPBase v2.0: decoding transcriptional regulatory networks of non-coding RNAs and protein-coding genes from ChIP-seq data. Nucleic Acids Res. 2017;45:D43–d50.

    Article  CAS  PubMed  Google Scholar 

  39. Wu K, Yu Z, Tang Z, Wei W, Xie D, Xie Y, et al. miR-877-5p suppresses gastric cancer cell proliferation through targeting FOXM1. Onco Targets Ther. 2020;13:4731–42.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Enzo E, Secone Seconetti A, Forcato M, Tenedini E, Polito MP, Sala I, et al. Single-keratinocyte transcriptomic analyses identify different clonal types and proliferative potential mediated by FOXM1 in human epidermal stem cells. Nat Commun. 2021;12:2505.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Yi L, Wang H, Li W, Ye K, Xiong W, Yu H, et al. The FOXM1/RNF26/p57 axis regulates the cell cycle to promote the aggressiveness of bladder cancer. Cell Death Dis. 2021;12:944.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Wang SP, Wu SQ, Huang SH, Tang YX, Meng LQ, Liu F, et al. FDI-6 inhibits the expression and function of FOXM1 to sensitize BRCA-proficient triple-negative breast cancer cells to Olaparib by regulating cell cycle progression and DNA damage repair. Cell Death Dis. 2021;12:1138.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Li L, Wu D, Yu Q, Li L, Wu P. Prognostic value of FOXM1 in solid tumors: a systematic review and meta-analysis. Oncotarget 2017;8:32298–308.

    Article  PubMed  PubMed Central  Google Scholar 

  44. Liu C, Barger CJ, Karpf AR. FOXM1: a multifunctional oncoprotein and emerging therapeutic target in ovarian cancer. Cancers (Basel). 2021;13:3065.

    Article  CAS  PubMed  Google Scholar 

  45. Liu J, Li J, Wang K, Liu H, Sun J, Zhao X, et al. Aberrantly high activation of a FoxM1-STMN1 axis contributes to progression and tumorigenesis in FoxM1-driven cancers. Signal Transduct Target Ther. 2021;6:42.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. García-Cortés D, Hernández-Lemus E, Espinal-Enríquez J. Luminal A breast cancer co-expression network: structural and functional alterations. Front Genet. 2021;12:629475.

    Article  PubMed  PubMed Central  Google Scholar 

  47. Lv C, Zhao G, Sun X, Wang P, Xie N, Luo J, et al. Acetylation of FOXM1 is essential for its transactivation and tumor growth stimulation. Oncotarget 2016;7:60366–82.

    Article  PubMed  PubMed Central  Google Scholar 

  48. Wu XR, Chen YH, Liu DM, Sha JJ, Xuan HQ, Bo JJ, et al. Increased expression of forkhead box M1 protein is associated with poor prognosis in clear cell renal cell carcinoma. Med Oncol. 2013;30:346.

    Article  PubMed  Google Scholar 

  49. Zhang W, Duan N, Song T, Li Z, Zhang C, Chen X. The emerging roles of forkhead box (FOX) proteins in osteosarcoma. J Cancer. 2017;8:1619–28.

    Article  PubMed  PubMed Central  Google Scholar 

  50. Subhi O, Schulten HJ, Bagatian N, Al-Dayini R, Karim S, Bakhashab S, et al. Genetic relationship between Hashimoto`s thyroiditis and papillary thyroid carcinoma with coexisting Hashimoto`s thyroiditis. PLoS ONE. 2020;15:e0234566.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Yu H, Xu Z, Guo M, Wang W, Zhang W, Liang S, et al. FOXM1 modulates docetaxel resistance in prostate cancer by regulating KIF20A. Cancer Cell Int. 2020;20:545.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Bellelli R, Castellone MD, Garcia-Rostan G, Ugolini C, Nucera C, Sadow PM, et al. FOXM1 is a molecular determinant of the mitogenic and invasive phenotype of anaplastic thyroid carcinoma. Endocr Relat Cancer. 2012;19:695–710.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. Shirakawa J, Fernandez M, Takatani T, El Ouaamari A, Jungtrakoon P, Okawa ER, et al. Insulin signaling regulates the FoxM1/PLK1/CENP—a pathway to promote adaptive pancreatic β cell proliferation. Cell Metab. 2017;25:868–82.e5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Lokody I. Signalling: FOXM1 and CENPF: co-pilots driving prostate cancer. Nat Rev Cancer. 2014;14:450–1.

    Article  CAS  PubMed  Google Scholar 

  55. Zhao R, Xiong C, Zhang C, Wang L, Liang H, Luo X. Construction of a prognosis-related gene signature by weighted gene coexpression network analysis in Ewing sarcoma. Comput Math Methods Med. 2022;2022:8798624.

    PubMed  PubMed Central  Google Scholar 

  56. Xu W, Wang Y, Wang Y, Lv S, Xu X, Dong X. Screening of differentially expressed genes and identification of NUF2 as a prognostic marker in breast cancer. Int J Mol Med. 2019;44:390–404.

    CAS  PubMed  PubMed Central  Google Scholar 

  57. Lin J, Chen X, Yu H, Min S, Chen Y, Li Z, et al. NUF2 drives clear cell renal cell carcinoma by activating HMGA2 transcription through KDM2A-mediated H3K36me2 demethylation. Int J Biol Sci. 2022;18:3621–35.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  58. Xie X, Lin J, Fan X, Zhong Y, Chen Y, Liu K, et al. LncRNA CDKN2B-AS1 stabilized by IGF2BP3 drives the malignancy of renal clear cell carcinoma through epigenetically activating NUF2 transcription. Cell Death Dis. 2021;12:201.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. Sugimasa H, Taniue K, Kurimoto A, Takeda Y, Kawasaki Y, Akiyama T. Heterogeneous nuclear ribonucleoprotein K upregulates the kinetochore complex component NUF2 and promotes the tumorigenicity of colon cancer cells. Biochem Biophys Res Commun. 2015;459:29–35.

    Article  CAS  PubMed  Google Scholar 

  60. Guo L, Wu Z. FOXM1-mediated NUF2 expression confers temozolomide resistance to human glioma cells by regulating autophagy via the PI3K/AKT/mTOR signaling pathway. Neuropathology 2022;42:430–46.

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

The authors would like to thank Prof. Vincent Keng and Prof. Jilong Yang for providing cell lines.

Funding

This work was supported by grants from the National Natural Science Foundation of China (82102344; 82172228), the Shanghai Rising Star Program supported by the Science and Technology Commission of Shanghai Municipality (20QA1405600); Science and Technology Commission of Shanghai Municipality (19JC1413); Natural Science Foundation of Shanghai (22ZR1422300); “Chenguang Program” supported by Shanghai Education Development Foundation (SHEDF) (19CG18); Shanghai Municipal Key Clinical Specialty (shslczdzk00901); Innovative research team of high-level local universities in Shanghai (SSMU-ZDCX20180700); the Project of Biobank (YBKA201901) from Shanghai Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine.

Author information

Author notes

  1. These authors contributed equally: Rehanguli Aimaier, Man-Hon Chung, Yihui Gu, Qingxiong Yu.

Authors and Affiliations

  1. Department of Plastic and Reconstructive Surgery, Shanghai Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

    Rehanguli Aimaier, Man-Hon Chung, Yihui Gu, Chengjiang Wei, Zizhen Guo, Yuehua Li, Wei Wang, Qingfeng Li & Zhichao Wang

  2. Department of Facial Plastic and Reconstructive Surgery, Eye & ENT Hospital, Fudan University, Shanghai, China

    Qingxiong Yu

  3. Department of Plastic Surgery, The Third Xiangya Hospital, Central South University, Changsha, Hunan, China

    Haibo Li

  4. Department of Pathology, Shanghai Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

    Manmei Long

Authors
  1. Rehanguli Aimaier
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Man-Hon Chung
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yihui Gu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Qingxiong Yu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Chengjiang Wei
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Haibo Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Zizhen Guo
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Manmei Long
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Yuehua Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Wei Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Qingfeng Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Zhichao Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

QL, ZW, and RH contributed to the conceptualization and design of the experiment. RH, MC, YG, QY, YL, HL, and ZG contributed to the methodology, investigation, and data curation. YG, QY, CW, ML, and WW contributed to the software, validation, and visualization. QL and ZW contributed to the supervision and funding acquisition. All authors participated in data analysis and wrote and approved the final version of the paper.

Corresponding authors

Correspondence to Qingfeng Li or Zhichao Wang.

Ethics declarations

Ethics approval

The study was approved by the Ethics Committee of Shanghai Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine. Informed consent was obtained from all subjects involved in the study. The animal study protocol was approved by the Shanghai Medical Experimental Animal Care Commission (IACUC: 2019-0008).

Competing interests

The authors have no conflict of interest to declare.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Aimaier, R., Chung, MH., Gu, Y. et al. FOXM1 promotes neurofibromatosis type 1-associated malignant peripheral nerve sheath tumor progression in a NUF2-dependent manner. Cancer Gene Ther 30, 1390–1402 (2023). https://doi.org/10.1038/s41417-023-00645-8

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41417-023-00645-8

Search

Advanced search

Quick links